Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
Sandhu, S. et al. Prostate cancer. Lancet 398, 1075–1090 (2021).
Centenera, M. M. et al. A patient‐derived explant (PDE) model of hormone‐dependent cancer. Mol. Oncol. 12, 1608–1622 (2018).
Arriaga, J. M. & Abate-Shen, C. Genetically engineered mouse models of prostate cancer in the postgenomic era. Cold Spring Harb. Perspect. Med. 9, a030528 (2019).
Drost, J. et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat. Protoc. 11, 347–358 (2016).
Navone, N. M. et al. Movember GAP1 PDX project: an international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. Prostate 78, 1262–1282 (2018).
Gleave, A. M., Ci, X., Lin, D. & Wang, Y. A synopsis of prostate organoid methodologies, applications, and limitations. Prostate 80, 518–526 (2020).
Risbridger, G. P., Toivanen, R. & Taylor, R. A. Preclinical models of prostate cancer: patient-derived xenografts, organoids, and other explant models. Cold Spring Harb. Perspect. Med. 8, a030536 (2018).
Davies, A. H., Wang, Y. & Zoubeidi, A. Patient-derived xenografts: a platform for accelerating translational research in prostate cancer. Mol. Cell. Endocrinol. 462, 17–24 (2018).
van de Merbel, A. F., van der Horst, G. & van der Pluijm, G. Patient-derived tumour models for personalized therapeutics in urological cancers. Nat. Rev. Urol. 18, 33–45 (2021).
Inoue, T., Terada, N., Kobayashi, T. & Ogawa, O. Patient-derived xenografts as in vivo models for research in urological malignancies. Nat. Rev. Urol. 14, 267–283 (2017).
Risbridger, G. P., Lawrence, M. G. & Taylor, R. A. PDX: moving beyond drug screening to versatile models for research discovery. J. Endocr. Soc. 4, bvaa132 (2020).
Toivanen, R. et al. A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors. Sci. Transl. Med. 5, 187ra71 (2013).
Priolo, C. et al. Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. Am. J. Pathol. 176, 1901–1913 (2010).
Risbridger, G. P. et al. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nat. Commun. 12, 5049 (2021).
Wang, Y. et al. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab. Invest. 85, 1392–1404 (2005).
Palanisamy, N. et al. The MD anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development. Clin. Cancer Res. 26, 4933–4946 (2020).
Nguyen, H. M. et al. LuCaP prostate cancer patient‐derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics. Prostate 77, 654–671 (2017).
Woo, X. Y. et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat. Genet. 53, 86–99 (2021).
Gao, H. et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21, 1318–1325 (2015).
Conte, N. et al. PDX Finder: a portal for patient-derived tumor xenograft model discovery. Nucleic Acids Res. 47, D1073–D1079 (2019).
Krupke, D. M. et al. The mouse tumor biology database: a comprehensive resource for mouse models of human cancer. Cancer Res. 77, e67–e70 (2017).
Byrne, A. T. et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat. Rev. Cancer 17, 254 (2017).
Lin, D. et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 74, 1272–1283 (2014).
Marques, R. B. et al. The human PC346 xenograft and cell line panel: a model system for prostate cancer progression. Eur. Urol. 49, 245–257 (2006).
Brennen, W. N. et al. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. JCI Insight 6, e146827 (2021).
Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H. & Paulson, D. F. Isolation of a human prostate carcinoma cell line (DU145). Int. J. Cancer 21, 274–281 (1978).
Kaighn, M. E., Narayan, K. S., Ohnuki, Y., Lechner, J. F. & Jones, L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 17, 16–23 (1979).
Horoszewicz, J. et al. The LNCaP cell line — a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res. 37, 115–132 (1980).
Sobel, R. E. & Sadar, M. D. Cell lines used in prostate cancer research: a compendium of old and new lines — part 2. J. Urol. 173, 360–372 (2005).
Sobel, R. E. & Sadar, M. D. Cell lines used in prostate cancer research: a compendium of old and new lines — part 1. J. Urol. 173, 342–359 (2005).
Ghandi, M. et al. Next-generation characterization of the cancer cell line encyclopedia. Nature 569, 503–508 (2019).
Vargas, R. et al. Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response. NPJ Precis. Oncol. 2, 14 (2018).
Wensink, G. E. et al. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. NPJ Precis. Oncol. 5, 30 (2021).
Gao, D. et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159, 176–187 (2014).
Puca, L. et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat. Commun. 9, 2404 (2018).
Lawrence, M. G. et al. A preclinical xenograft model of prostate cancer using human tumors. Nat. Protoc. 8, 836–848 (2013).
Zhao, H., Nolley, R., Chen, Z. & Peehl, D. M. Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am. J. Pathol. 177, 229–239 (2010).
Erickson, A. et al. Spatially resolved clonal copy number alterations in benign and malignant tissue. Nature 608, 360–367 (2022).
Porter, L. H. et al. Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate‐tolerant cells. BJU Int. 121, 971–978 (2018).
Risbridger, G. P. et al. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur. Urol. 67, 496–503 (2015).
Pauli, C. et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 7, 462–477 (2017).
Servant, R. et al. Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens. J. Pathol. 254, 543–555 (2021).
Welti, J. et al. Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC). Clin. Cancer Res. 24, 3149–3162 (2018).
Nguyen, H. G. et al. Development of a stress response therapy targeting aggressive prostate cancer. Sci. Transl. Med. 10, eaar2036 (2018).
Mout, L. et al. Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells. Eur. J. Cancer 150, 179–189 (2021).
Cyrta, J. et al. Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nat. Commun. 11, 5549 (2020).
Lee, S. et al. Establishment and analysis of three-dimensional (3D) organoids derived from patient prostate cancer bone metastasis specimens and their xenografts. J. Vis. Exp. 156, e60367 (2020).
留言 (0)